888-969-2592
Kalkine 0
countryflagCA

Theratechnologies Inc.

Healthcare CA TH

3.3CAD
0.10(3.12%)

Last update at 2025-06-27T16:32:00Z

Day Range

3.103.30
LowHigh

52 Week Range

1.594.33
LowHigh

Fundamentals

  • Previous Close 3.20
  • Market Cap155.41M
  • Volume69932
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA14.72M
  • Revenue TTM88.67M
  • Revenue Per Share TTM1.80
  • Gross Profit TTM 70.02M
  • Diluted EPS TTM-0.1

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Type yearly yearly yearly yearly yearly
Date 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Income before tax -46.79400M -31.66200M -22.65100M -12.49600M -5.78041M
Minority interest - - - - -
Net income -47.23700M -31.72500M -22.66700M -12.54700M -4.52868M
Selling general administrative 17.36M 14.62M 12.23M 8.33M 5.69M
Selling and marketing expenses 39.39M 28.91M 26.86M 26.48M 21.08M
Gross profit 53.78M 46.56M 39.15M 37.14M 31.13M
Reconciled depreciation 12.47M 8.75M 8.52M 7.50M 4.15M
Ebit -39.90800M -25.23600M -17.95700M -7.45500M -3.30105M
Ebitda -27.15600M -16.32400M -9.17800M 0.04M 0.85M
Depreciation and amortization 12.75M 8.91M 8.78M 7.50M 4.15M
Non operating income net other - - - - -
Operating income -39.90800M -25.23600M -17.95700M -7.45500M -3.41553M
Other operating expenses 119.97M 95.06M 84.01M 71.73M 47.51M
Interest expense 6.50M 5.66M 5.36M 4.99M 2.48M
Tax provision 0.44M 0.06M 0.02M 0.00000M -1.26900M
Interest income 7.21M 0.20M 4.65M 3.94M 2.37M
Net interest income -6.21600M -6.42600M -5.10300M -3.93200M -2.20296M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.44M 0.06M 0.02M 0.05M -1.25173M
Total revenue 80.06M 69.82M 66.05M 63.22M 44.10M
Total operating expenses 93.69M 71.80M 57.11M 45.65M 34.54M
Cost of revenue 26.28M 23.26M 26.90M 26.08M 12.97M
Total other income expense net -6.88600M -6.42600M -4.69400M -5.04100M -2.36489M
Discontinued operations - - - - -
Net income from continuing ops -47.23700M -31.72500M -22.66700M -12.49600M -4.52868M
Net income applicable to common shares -47.23700M -31.72500M -22.66700M -12.49600M -4.70000M
Preferred stock and other adjustments - - - - -
Breakdown 2024-11-30 2023-11-30 2022-11-30 2021-11-30 2020-11-30
Type yearly yearly yearly yearly yearly
Date 2024-11-30 2023-11-30 2022-11-30 2021-11-30 2020-11-30
Total assets 53.34M 77.77M 93.26M 119.21M 100.14M
Intangible assets 7.57M 12.50M 15.01M 23.83M 31.85M
Earning assets - - - - -
Other current assets - 3.29M 8.27M 11.48M 5.71M
Total liab 78.61M 98.64M 115.83M 101.45M 96.92M
Total stockholder equity -25.27200M -20.87000M -22.57100M 17.76M 3.22M
Deferred long term liab - - 1.79M 0.62M -
Other current liab 0.96M 32.56M 36.09M 58.07M 23.93M
Common stock - 363.93M 338.75M 335.75M 287.31M
Capital stock 363.93M 363.93M 338.75M 335.75M 287.31M
Retained earnings -416.88700M -408.65900M -382.64900M -335.24800M -300.12900M
Other liab - - 0.11M 0.09M 0.04M
Good will - - - - -
Other assets - - 1.79M 0.62M -
Cash 5.90M 34.10M 23.86M 20.40M 12.74M
Cash and equivalents - - 9.21M 19.95M 8.03M
Total current liabilities 36.86M 47.29M 114.28M 45.08M 41.92M
Current deferred revenue - 0.04M 0.04M 0.05M 0.05M
Net debt 38.53M 24.87M 42.85M 36.35M 42.65M
Short term debt - 7.71M 65.27M 0.46M 0.42M
Short long term debt 3.49M 7.29M 64.79M - -
Short long term debt total - 58.97M 66.71M 56.74M 55.38M
Other stockholder equity - 23.18M 20.94M 17.30M 16.52M
Property plant equipment - - 3.09M 2.85M 3.48M
Total current assets 43.98M 63.30M 73.37M 91.91M 64.81M
Long term investments 0.21M - - - 0.00000M
Net tangible assets - - -37.58000M -6.06900M -28.62800M
Short term investments 3.72M 6.29M 9.21M 19.95M 8.03M
Net receivables 14.97M 13.55M 12.34M 10.93M 13.19M
Long term debt 40.94M 50.69M 0.00000M 54.23M 52.40M
Inventory 5.28M 6.07M 19.69M 29.14M 25.14M
Accounts payable 6.33M 6.99M 12.89M 15.53M 17.51M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.68M 0.39M -0.04400M -0.48100M
Additional paid in capital - - - - -
Common stock total equity - - - - 287.31M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 1.79M 0.62M -
Deferred long term asset charges - - - - -
Non current assets total 9.36M 14.47M 19.89M 27.30M 35.34M
Capital lease obligations 1.17M 0.99M 1.92M 2.52M 2.98M
Long term debt total - - 1.45M 56.28M 54.96M
Breakdown 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Type yearly yearly yearly yearly yearly
Date 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Investments 8.68M -12.11600M 4.78M -0.13000M -10.69094M
Change to liabilities -1.11600M 5.55M 3.42M 6.18M 6.13M
Total cashflows from investing activities 8.68M -12.45400M 4.78M -0.13000M -9.91800M
Net borrowings 10.65M -5.63500M -4.06800M -3.50000M 49.65M
Total cash from financing activities 9.66M 34.56M -7.22900M -6.80700M 46.89M
Change to operating activities 6.81M -3.02000M -2.58300M -0.81200M -0.38000M
Net income -47.23700M -31.72500M -22.66700M -12.49600M -4.52868M
Change in cash 3.46M 7.66M -15.92400M -10.33600M 37.72M
Begin period cash flow 20.40M 12.74M 28.66M 39.00M 1.33M
End period cash flow 23.86M 20.40M 12.74M 28.66M 39.04M
Total cash from operating activities -14.69200M -14.47700M -13.55400M -3.39100M -0.33440M
Issuance of capital stock 2.96M 46.00M - - 0.00000M
Depreciation 12.47M 8.75M 8.52M 7.50M 4.15M
Other cashflows from investing activities 9.67M -0.17200M 0.36M 1.20M 0.75M
Dividends paid - 0.00000M 0.00000M 0.00000M -
Change to inventory 8.99M -4.18700M -4.87200M -9.86100M -3.90131M
Change to account receivables -1.66900M 1.85M -2.25300M 0.83M -3.40649M
Sale purchase of stock 2.98M 47.34M 0.14M 0.11M 0.63M
Other cashflows from financing activities 36.05M -10.81000M -6.66100M -6.80700M 57.07M
Change to netincome 7.06M 8.26M 6.87M 5.27M 2.20M
Capital expenditures 0.98M 0.17M 0.03M 3.62M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 13.02M 0.24M -6.27400M -3.66200M -0.03690M
Stock based compensation 3.87M 1.93M 1.43M 1.09M 0.83M
Other non cash items 2.74M 6.33M 5.44M 4.18M 0.51M
Free cash flow -15.67700M -14.64300M -13.58600M -7.01300M -0.37356M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TH
Theratechnologies Inc.		 0.10 3.12% 3.30 - 24.75 1.75 19.46 1.79 15.71
FRX
Fennec Pharmaceuticals Inc		 -0.11 0.97% 11.22 - 11.95 10.33 57.98 6.90 20.27
EPRX
Eupraxia Pharmaceuticals Inc		 0.52 8.15% 6.90 - - - 82.33 -3.8823
MSCL
Satellos Bioscience Inc.		 -0.02 3.28% 0.59 2.40 - - 1.74 6.47
ONC
Oncolytics Biotech Inc		 0.08 8.16% 1.06 - - - 11.76 -2.4457

Reports Covered

Stock Research & News

View All

Profile

Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Theratechnologies Inc.

2015 Peel Street, Montreal, QC, Canada, H3A 1T8

Key Executives

Name Title Year Born
Mr. Paul Lévesque Pres, CEO & Director 1964
Mr. Philippe Dubuc M.B.A., MBA Sr. VP & CFO 1967
Dr. Christian Marsolais Ph.D. Sr. VP & Chief Medical Officer 1963
Mr. John Leasure Global Commercial Officer 1965
Ms. Elif McDonald Sr. Director of Investor Relations NA
Mr. Jocelyn Lafond L.L.M., LL.B. Gen. Counsel & Corp. Sec. 1968
Mr. Denis Boucher B.A., L.L.B. VP of Communications & Corp. Affairs 1966
Hon. Andre Dupras M.Sc. VP of HR 1964
Mr. Paul Lévesque President, CEO & Director 1964
Mr. Philippe Dubuc M.B.A., MBA Senior VP & CFO 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.